All the news Showing 10 of 30 articles from: Genotype 4Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources OLYSIO™ (simeprevir) receives marketing authorisation in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection Reuters / 16 May 2014 Sofosbuvir for hepatitis C works well despite multiple negative predictive factors Liz Highleyman / 24 April 2014 Hepatitis C treatment using sofosbuvir (Sovaldi) is highly effective even for people with multiple factors traditionally associated with poor response. Having four or more negative predictive factors, however, raises the risk of post-treatment relapse, ... AbbVie 2-drug combination + ribavirin achieves 100% cure in previously untreated genotype 4 hepatitis C Keith Alcorn / 22 April 2014 A combination of two direct-acting antivirals developed by AbbVie cured 100% of previously untreated patients with hepatitis C genotype 4 infection when used with ribavirin, Christophe Hézode reported on Friday at the ... European liver specialists recommend use of newest hepatitis C drugs Keith Alcorn / 12 April 2014 The European Association for the Study of the Liver (EASL) has issued new guidelines for the treatment of hepatitis C which recommend that wherever possible, patients should be treated with ... US medical societies launch new hepatitis C treatment guidelines Liz Highleyman / 30 January 2014 The American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA) and International Antiviral Society-USA (IAS-USA) yesterday announced the first new hepatitis C treatment guidelines ... European Commission Grants Marketing Authorization for Gilead’s Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection Gilead press release / 17 January 2014 Egyptians hold their breath as new Hepatitis C drugs promise cure Ahram Online / 24 December 2013 FDA Panel Backs Sofosbuvir for Hepatitis C Medscape / 28 October 2013 Simeprevir with interferon effective in genotype 4 HCV infection and for HIV/HCV co-infected people with genotype 1 hepatitis C Liz Highleyman / 21 October 2013 Adding the direct-acting hepatitis C drug simeprevir to pegylated interferon and ribavirin produced high response rates for HIV-positive people co-infected with HCV genotype 1, researchers reported at the 14th European AIDS ... Sofosbuvir + interferon/ribavirin cures 90% of people with hard-to-treat hepatitis C genotypes Liz Highleyman / 04 May 2013 Adding the second-generation HCV polymerase inhibitor sofosbuvir (formerly GS-7977) to pegylated interferon plus ribavirin led to a sustained response rate of 89% for treatment-naive patients with HCV genotype 1 in the NEUTRINO study, ... ← Prev123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive